By no means an expert,...... But looking at the company, while we have a considerable amount of clinical evidence to further support proof of concept (results from 20 +/- patients), an EFS started recruiting (with an estimated end point within the next 6 ish months), and clinical evidence that suggests VIV is another avenue to explore (and potentially dominate), we are still some time (about 1000 patients in the next phase of the series of trials) before we will have a commercial product - and the ability for the company to make money. This is a considerable variable (IMO) that will likely have an impact on public perception of the company, its financial future, and ultimately the SP.
The next phase of the trials allows the product to be sold (a reportedly $25 000) in the trial which will take the pressure of the finances ($25 million for 1000 participants), but still is not enough for financial stability.
As I see it, once the company can sell the product, in non study circumstances, the financial situation will be more attractive which may reflect in an increase in SP. I am hoping it will happen, but believe that it may take a little longer that some hope.
Just my 2c ($20 post consolidation/s) worth. Not advice. DYOR.
AVR Price at posting:
$19.08 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)